According to a recent LinkedIn post from ViGenCell(바이젠셀), the company’s Phase 2 clinical study of its cell therapy candidate ‘VT-EBV-N’ has been selected for an Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 in Chicago. The post notes this is described as the first case of a Korean company being chosen for an official ASCO oral presentation based on cell therapy clinical data, highlighting the competitive nature of selection from thousands of submitted abstracts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that this visibility at one of the world’s leading oncology conferences could enhance ViGenCell’s profile in the global oncology and cell therapy markets and potentially strengthen its position in partnering and licensing discussions. For investors, the selection may signal growing scientific recognition of VT-EBV-N and could be a catalyst for future business development, though clinical, regulatory, and commercialization outcomes remain uncertain and will depend on full data, peer reception, and subsequent trials.